

Res. Asst. HAKAN TABAN

Personal Information

Email: hakantaban@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/hakantaban>

Education Information

Expertise In Medicine, Hacettepe University, Tıp Fakültesi, İç Hastalıkları, Turkey 2013 - Continues

Undergraduate, Marmara University, School Of Medicine, Turkey 2006 - 2012

Foreign Languages

English, B2 Upper Intermediate

Italian, A1 Beginner

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer**
Ceylan F., Guven D. C., Taban H., Aktepe O., ŞAHİN T. K., Kilickap S., Turker A., Hamaloglu E., KARAKOÇ D., Isik A., et al.
Clinics and Research in Hepatology and Gastroenterology, vol.47, no.3, 2023 (SCI-Expanded)
- II. **Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease**
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKSOY S., ERMAN M., Kilickap S., YALÇIN Ş.
JOURNAL OF CLINICAL MEDICINE, vol.11, no.17, 2022 (SCI-Expanded)
- III. **Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience**
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., GÜVEN D. C., Olgun P., KERTMEN N., DİZDAR Ö., et al.
FUTURE ONCOLOGY, vol.18, pp.323-331, 2022 (SCI-Expanded)
- IV. **Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better? Comment**
Guven D. C., Taban H., Dizdar O.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.28, no.1, pp.203-204, 2022 (SCI-Expanded)
- V. **Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database**
Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., Arikan R., Arslan C., TABAN H., Kucukarda A., et al.
FUTURE ONCOLOGY, vol.17, pp.4861-4869, 2021 (SCI-Expanded)
- VI. **Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-**

checkpoint inhibitors

GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., ŞAHİN T. K., AKSUN M. S., DİZDAR Ö., AKSOY S., et al.

BIOMARKERS IN MEDICINE, vol.15, no.13, pp.1123-1130, 2021 (SCI-Expanded)

VII. **Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy**

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., Ceylan F., KERTMEN N., ARIK Z., DİZDAR Ö., et al.

SUPPORTIVE CARE IN CANCER, vol.29, no.9, pp.5417-5423, 2021 (SCI-Expanded)

VIII. **PILE: a candidate prognostic score in cancer patients treated with immunotherapy**

Güven D. C., Yildirim H. C., Bilgin E., Aktepe O. H., Taban H., Sahin T. K., Cakir I. Y., Akin S., Dizdar O., Aksoy S., et al.
CLINICAL & TRANSLATIONAL ONCOLOGY, vol.23, no.8, pp.1630-1636, 2021 (SCI-Expanded)

IX. **Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors**

GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., AKKAŞ M., ERMAN M., KILIÇKAP S., DİZDAR Ö., et al.

SUPPORTIVE CARE IN CANCER, vol.29, no.4, pp.2029-2035, 2021 (SCI-Expanded)

X. **Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.**

Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., Arslan C., TABAN H., Kucukarda A., ŞENTÜRK ÖZTAŞ N., et al.

JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.6, 2021 (SCI-Expanded)

XI. **Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience**

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., TABAN H., GÜVEN D. C., KERTMEN N., Oksuzoglu B., et al.
CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)

XII. **Prognostic and predictive value of tumor-infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer**

Efil S. C., Guner G., Guven D. C., Celikten B., Celebiyev E., Taban H., Akyol A., Kilickap S., YALÇIN S. S., Dizdar O.
ANNALS OF ONCOLOGY, vol.32, 2021 (SCI-Expanded)

XIII. **What to expect from NCCN BRCA testing criteria: A retrospective cohort analysis**

Aktas B. Y., Degirmenciler R. F., Durmaz C. D., Taban H., Guven D. C., Guner G., Yildirim H. C., Demir M., Kertmen N., Arik Z., et al.

ANNALS OF ONCOLOGY, vol.32, 2021 (SCI-Expanded)

XIV. **Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)**

HIZAL M., ŞENDUR M. A. N., YAŞAR H. A., Bir Yucel K., Arslan C., Ucar G., Karakaya S., TABAN H., Kucukarda A., Erturk I., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.7, pp.1583-1589, 2020 (SCI-Expanded)

XV. **Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design**

GÜVEN D. C., GÜNER G., AKTAŞ B. Y., AKTEPE O. H., TABAN H., ARIK Z.
CLINICAL COLORECTAL CANCER, vol.19, no.3, 2020 (SCI-Expanded)

XVI. **The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer**

YAŞAR H. A., Yucel K. B., Arslan C., Ucar G., Karakaya S., Bilgin B., TABAN H., Kucukarda A., Erturk I., Hizal M., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.5, pp.1110-1116, 2020 (SCI-Expanded)

XVII. **Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer**

GÜVEN D. C., KILIÇKAP S., GÜNER G., TABAN H., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.1, pp.256-258, 2020 (SCI-Expanded)

Articles Published in Other Journals

- I. **Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience**
DEMİR M., Guven D., AKTAŞ B. Y., GÜNER G., AKTEPE O. H., TABAN H., Karakas Y., Kilickap S., Kars A., Turker A., et al.
SOUTH ASIAN JOURNAL OF CANCER, vol.11, pp.287-292, 2022 (ESCI)
- II. **Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report**
TABAN H., GÜVEN D. C., Kilickap S.
CUREUS JOURNAL OF MEDICAL SCIENCE, vol.14, no.8, 2022 (ESCI)
- III. **Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy**
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKTAŞ B. Y., GÜNER G., DİZDAR Ö., AKSOY S., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.6, no.1, pp.59-63, 2022 (ESCI)
- IV. **Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy**
YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., KUŞ F., AKYILDIZ A., GÜRBÜZ S. Ç., Sayin H., et al.
Journal of Oncological Science, vol.8, no.3, pp.143-147, 2022 (Scopus)
- V. **Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma**
AKTEPE O. H., GÜNER G., GÜVEN D. C., TABAN H., YILDIRIM H. Ç., ŞAHİN T. K., Ardic F. S., Yeter H. H., YÜCE D., ERMAN M.
TURKISH JOURNAL OF UROLOGY, vol.47, no.2, pp.113-119, 2021 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

- I. **Prognostic role of tumoral DNA damage repair protein expression in patients with resectable pancreatic cancer**
Ceylan F., Guven D. C., Taban H., Aktepe O., Kilickap S., Turker A., Hamaloglu E., Karakoc D., Isik A., Akyol A., et al.
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- II. **Daily chemotherapy and treatment unit in the COVID-19 era: Lessons of the first 60 days**
Aktas B. Y., Guven D. C., Degirmenciler R. F., Taban H., Aktepe O. H., Kertmen N., Kilickap S., Dizdar O., Aksoy S., Erman M., et al.
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- III. **Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience**
AKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Guven D. C., AKTEPE O. H., Guner G., Taban H., KERTMEN N., ARIK Z., DİZDAR Ö.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30
- IV. **Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital**
Guven D. C., AKTEPE O. H., Berk Z., Guner G., Taban H., AKTAŞ B. Y., Duran Z. C., AKIN Ş., ARIK Z., KERTMEN N., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30
- V. **Clinical features and prognosis of patients with liposarcoma: Single-center experience.**
Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., Kilickap S., Kars A., Turker A., Yalcin S., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37

Metrics

Publication: 27

Citation (WoS): 2

Citation (Scopus): 22

H-Index (WoS): 1

H-Index (Scopus): 3